Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    0.00 (0.00%)
Bid:
26.10
Ask:
27.40
Spread: 1.30 (4.981%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Board Changes

27 Apr 2026 07:00

RNS Number : 9952B
EKF Diagnostics Holdings PLC
27 April 2026
 

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Board Changes

Appointment of Chief Financial Officer

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, announces the appointment of Helen Jones FCA as Chief Financial Officer ("CFO"). Helen will join the Board and assume the role of CFO with immediate effect.

 

Helen Jones is an experienced CFO with over 20 years' experience leading finance, operations, and strategic transactions in high-growth, technology-driven AIM listed businesses.

 

Helen joins EKF from Surgical Science, a leading provider of medical simulation solutions, where she has assumed a senior Group-level role following its acquisition of Intelligent Ultrasound Group plc in February 2025, with responsibility spanning post-acquisition integration and operational cost reduction, Group statutory reporting, and sustainability leadership. Prior to the acquisition, Helen spent five years as CFO of Intelligent Ultrasound Group plc, an AIM-listed company supplying simulation and AI-based ultrasound training solutions to the healthcare sector. During her tenure, Helen led two successful equity placings to fund growth and innovation, played a central role in both the £40.6 million divestment of its Clinical AI division to GE Healthcare and the subsequent sale of the Simulation business to Surgical Science.

 

Before joining Intelligent Ultrasound, Helen held a senior finance role within AIM-listed oil and exploration company Amerisur Resources plc and prior to that spent 11 years in various senior financial positions at Tata Steel Europe. Helen is a fellow of the Institute of Chartered Accountants in England and Wales having trained and qualified with PwC in 2004.

 

Helen succeeds Stephen Young, who is retiring from the Board. Steve will be available to support Helen to ensure a smooth handover but will step down from the Board with immediate effect. The Board would like to extend its sincere thanks to Steve for his financial stewardship since joining the Company in September 2023 and wishes him well in his retirement.

 

 

Commenting, Gavin Jones, Chief Executive Officer, said: "We are delighted to welcome Helen to the EKF team at a key time as we execute on our five-year development plan for accelerated growth. Helen's track record in listed healthcare technology businesses, her experience executing complex transactions, and her capital markets expertise make her an excellent fit for EKF as we accelerate our five-year plan. Her appointment reflects our commitment to building a leadership team capable of delivering our ambitious growth targets."

 

Additional Disclosures Required under the AIM Rules for Companies

The following additional information is provided with regards to the appointment of Helen Mary Kinsey Jones (aged 47) in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

 

Current Directorships/partnerships

Directorships/partnerships within the last five years:

None

IML Finance Limited

Intelligent Ultrasound Innovations Limited

Intelligent Ultrasound Limited

Intelligent Ultrasound North America Inc

Inventive Medical Limited

Medaphor International Limited

Surgical Science UK Limited

Surgical Science UK Holdings Limited

 

Helen does not hold any shares or options in the Company.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

The person responsible for arranging the release of this Announcementon behalf of the Company is Gavin Jones, Chief Executive Officer.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Gavin Jones, Chief Executive Officer

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Patrick Weaver

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

Point-of-Care analysers in the key areas of Hematology and Diabetes 

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAESMEMSEFL
Date   Source Headline
24th Jul 20247:00 amRNSTrading Update
14th May 20241:15 pmRNSResult of AGM and Voting Results
14th May 202410:17 amRNSAGM Statement & Positive Q1 update (replacement)
14th May 20247:00 amRNSAGM Statement & Positive Q1 Trading update
22nd Apr 202411:53 amRNSPosting of Annual Report & Notice of AGM
25th Mar 20245:15 pmRNSDirector/PDMR Shareholding
20th Mar 20248:30 amRNSFinal Results
15th Mar 20247:00 amRNSInvestor Presentation – Revised start time
11th Mar 20247:00 amRNSNotice of Results and Investor Presentation
29th Jan 20247:00 amRNSTrading Update
11th Jan 20247:00 amRNSDirector/PDMR Shareholding
3rd Jan 20244:14 pmRNSHolding(s) in Company
29th Nov 20234:55 pmRNSHolding(s) in Company
26th Oct 20237:00 amRNSOpening of new US LS Manufacturing Facility
26th Sep 20237:00 amRNSInterim results
14th Sep 20237:00 amRNSNotice of Results & Investor Presentation
12th Sep 20237:01 amRNSTrading Update
12th Sep 20237:00 amRNSAppointment of CFO
26th Jul 20237:00 amRNSTrading Update
28th Jun 20237:00 amRNSDirectorate Change
20th Jun 20237:00 amRNSEnzyme fermentation capacity expansion progress
1st Jun 202311:07 amRNSHolding(s) in Company
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
22nd May 20232:52 pmRNSHolding(s) in Company
17th May 202311:50 amRNSResult of AGM and Voting Results
17th May 20237:00 amRNSAGM Statement
3rd May 20237:00 amRNSSuccessful quality management audits
25th Apr 20234:10 pmRNSTotal Voting Rights
21st Apr 20232:30 pmRNSPosting of Annual Report & Notice of AGM
28th Mar 20237:00 amRNSFinal Results
23rd Mar 20237:00 amRNSDisposal of ADL Health
1st Mar 20237:00 amRNSNotice of Results and Investor Presentation
21st Feb 20233:31 pmRNSHolding(s) in Company
10th Feb 20233:12 pmRNSHolding(s) in Company
6th Feb 20237:00 amRNSTrading update
9th Jan 20237:00 amRNSChange of Adviser
22nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
22nd Dec 20224:35 pmRNSPrice Monitoring Extension
22nd Dec 20227:00 amRNSPoint-of-Care update
15th Dec 20224:52 pmRNSHolding(s) in Company
14th Dec 20224:32 pmRNSHolding(s) in Company
6th Dec 20225:30 pmRNSHolding(s) in Company
14th Nov 20225:52 pmRNSHolding(s) in Company
20th Sep 20227:01 amRNSDividend Timetable
20th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSNotice of Interim Results & Investor Presentation
1st Aug 20227:00 amRNSTrading Update
29th Jun 20224:41 pmRNSSecond Price Monitoring Extn
29th Jun 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.